Skip to content

Study · Animal study (in vivo) · rat · 2021

9 results

Complex Syndrome of the Complete Occlusion of the End of the Superior Mesenteric Vein, Opposed with the Stable Gastric Pentadecapeptide BPC 157 in Rats.

Knezevic M, Gojkovic S, Krezic I, Zizek H, Vranes H, Malekinusic D, Vrdoljak B, Knezevic T, Horvat Pavlov K, Drmic D, Staroveski M, Djuzel A and 17 more

Show all authors

Rajkovic Z, Kolak T, Lovric E, Milavic M, Sikiric S, Barisic I, Tepes M, Tvrdeic A, Patrlj L, Strbe S, Sola M, Situm A, Kokot A, Boban Blagaic A, Skrtic A, Seiwerth S, Sikiric P

Biomedicines17 Aug 2021Cited by 35 (Europe PMC)

PMID34440233 (opens in a new tab)PMCIDPMC8394093 (opens in a new tab)DOI10.3390/biomedicines9081029 (opens in a new tab)PepBankPUB-34440233
Download PDFPubMedAsk about this study
Jump to 9 results

Summary

Background. Gastric pentadecapeptide BPC 157 therapy in rats compensated irremovable occlusion of various vessels and counteracted the consequent multiorgan dysfunction syndromes by activation of the corresponding collateral bypassing loops. Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein. Methods. Assessments, for 30 min (gross recording, venography, ECG, pressure, microscopy, biochemistry, and oxidative stress) include the portal and caval hypertension, aortal hypotension, and centrally, the superior sagittal sinus hypertension, systemic arterial and venous thrombosis, ECG disturbances, MDA-tissue increase, and heart, lung, liver, kidney and gastrointestinal tract, in particular, and brain (cortex (cerebral, cerebellar), hypothalamus/thalamus, hippocampus) lesions. Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time. Results. BPC 157 rapidly activated the superior mesenteric vein-inferior anterior pancreati-coduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, reestablished superior mesenteric vein and portal vein connection and reestablished blood flow. Simultaneously, toward inferior caval vein, an additional pathway appears via the inferior mesenteric vein united with the middle colic vein, throughout its left colic branch to ascertain alternative bypassing blood flow. Consequently, BPC 157 acts peripherally and centrally, and counteracted the intracranial (superior sagittal sinus), portal and caval hypertension, aortal hypotension, ECG disturbances attenuated, abolished progressing venous and arterial thrombosis. Additionally, BPC 157 counteracted multiorgan dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal tract, and brain lesions, and oxidative stress in tissues. Conclusion. BPC 157 therapy may be specific management also for the superior mesenteric vein injuries.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 activated a bypass pathway to the portal vein and reestablished superior mesenteric vein to portal vein connection and blood flow.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 opened a bypass route and restored blood flow.

    Peptide
    BPC-157
    Outcome
    IncreaseCollateral pathway activation and blood flow after SMV occlusion
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 rapidly activated the superior mesenteric vein-inferior anterior pancreati-coduodenal vein-superior anterior pancreaticoduodenal vein-pyloric vein-portal vein pathway, reestablished superior mesenteric vein and portal vein connection and reestablished blood flow.
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 opened an additional pathway toward the inferior caval vein via the inferior mesenteric and middle colic veins.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 opened a second bypass route for blood flow.

    Peptide
    BPC-157
    Outcome
    IncreaseAlternative bypass toward the inferior caval vein
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    Simultaneously, toward inferior caval vein, an additional pathway appears via the inferior mesenteric vein united with the middle colic vein, throughout its left colic branch to ascertain alternative bypassing blood flow.
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 counteracted intracranial (superior sagittal sinus) hypertension.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 reduced raised pressure in the brain's main vein.

    Peptide
    BPC-157
    Outcome
    DecreaseIntracranial (superior sagittal sinus) hypertension
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    counteracted the intracranial (superior sagittal sinus), portal and caval hypertension
    1 context sentence
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 counteracted portal and caval hypertension.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 reduced raised pressure in two large abdominal veins.

    Peptide
    BPC-157
    Outcome
    DecreasePortal and caval hypertension
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    counteracted the intracranial (superior sagittal sinus), portal and caval hypertension, aortal hypotension
    1 context sentence
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 counteracted aortal hypotension.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 worked against the low aortic pressure.

    Peptide
    BPC-157
    Outcome
    IncreaseAortal hypotension
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    counteracted the intracranial (superior sagittal sinus), portal and caval hypertension, aortal hypotension
    1 context sentence
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 attenuated ECG disturbances.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 reduced heart rhythm trace disturbances.

    Peptide
    BPC-157
    Outcome
    DecreaseECG disturbances
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    ECG disturbances attenuated, abolished progressing venous and arterial thrombosis.
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 abolished progressing venous and arterial thrombosis.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 stopped blood clots from progressing in veins and arteries.

    Peptide
    BPC-157
    Outcome
    DecreaseVenous and arterial thrombosis
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    abolished progressing venous and arterial thrombosis.
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 counteracted multiorgan dysfunction syndrome, with heart, lung, liver, kidney, gastrointestinal tract and brain lesions.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 reduced damage to the heart, lungs, liver, kidneys, gut and brain.

    Peptide
    BPC-157
    Outcome
    DecreaseMultiorgan dysfunction syndrome and organ lesions
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    BPC 157 counteracted multiorgan dysfunction syndrome, heart, lung, liver, kidney and gastrointestinal tract, and brain lesions
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats with superior mesenteric vein occlusion, BPC‑157 counteracted oxidative stress in tissues.

    In plain wordsIn rats with a blocked abdominal vein, BPC‑157 reduced oxidative stress in tissues.

    Peptide
    BPC-157
    Outcome
    DecreaseTissue oxidative stress
    Study

    ratn: not reported in source

    Complete occlusion of the end of the superior mesenteric vein
    Outcome group
    Inflammation markers · Cardiovascular
    Studied dose
    10 µg/kg and 10 ng/kg · intraperitonealAs given in this study (rat).

    Source sentences

    Summary
    and oxidative stress in tissues.
    2 context sentences
    Summary · context
    Thus, we used BPC 157 therapy against the irremovable occlusion of the end of the superior mesenteric vein.
    Summary · context
    Rats received BPC 157 medication (10 µg/kg, 10 ng/kg) intraperitoneally at 1 or 15 min ligation time.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:56 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.